Clearside Biomed Financials
Clearside Biomed (CLSD) reported $1.7M in revenue for fiscal year 2024, down 79.8% from the prior fiscal year. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 11 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Clearside remains an R&D-led business whose cash needs are met by financing, not by recurring commercial revenue.
In FY2024, R&D spending of$18.6M against revenue of$1.7M shows a company still financing development far ahead of commercialization, so weak sales are not yet the main constraint on profitability; the research model is. Because operations used-$24.7M in cash while financing added$16.4M , liquidity is being sustained externally even though the business remains asset-light.
The FY2021 revenue spike to
FY2024 ended with cash of
Financial Health Signals
Scored against emerging companies for FY2024. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Clearside Biomed's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Clearside Biomed, and counted as zero in the overall score.
Not available for Clearside Biomed, and counted as zero in the overall score.
Clearside Biomed scores -22.72, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($2.1M) relative to total liabilities ($64.0M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Clearside Biomed passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, all 2 leverage/liquidity signals pass, neither operating efficiency signal passes.
Clearside Biomed reported a net loss of $34.4M while operations used $24.7M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Clearside Biomed generated $1.7M in revenue in fiscal year 2024. This represents a decrease of 79.8% from the prior year.
Clearside Biomed's EBITDA was -$29.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 17.6% from the prior year.
Clearside Biomed reported -$34.4M in net income in fiscal year 2024. This represents a decrease of 5.7% from the prior year.
Clearside Biomed earned -$0.47 per diluted share (EPS) in fiscal year 2024. This represents an increase of 11.3% from the prior year.
Cash & Balance Sheet
Clearside Biomed recorded an outflow of $25.7M in free cash flow in fiscal year 2024, representing a cash shortfall after capex. This represents a decrease of 28.9% from the prior year.
Clearside Biomed held $20.0M in cash as of fiscal year 2024; long-term debt is not reported for that period.
Not reported for fiscal year 2024.
Margins & Returns
Clearside Biomed's gross margin was 91.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs. This is down 4.6 percentage points from the prior year.
Not shown for fiscal year 2024: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not shown for fiscal year 2024: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.
Not reported for fiscal year 2024.
Capital Allocation
Clearside Biomed invested $18.6M in research and development in fiscal year 2024. This represents a decrease of 10.8% from the prior year.
Clearside Biomed invested $977K in capex in fiscal year 2024, funding long-term assets and infrastructure. This represents a decrease of 45.0% from the prior year.
Not reported for fiscal year 2024.
CLSD Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.3M | $1.7M-79.8% | $8.2M+519.9% | $1.3M-95.5% | $29.6M+274.7% | $7.9M+263.3% | $2.2M+7143.3% | $30K-91.3% | $345K-33.7% | $520K | N/A | N/A |
| Cost of Revenue | $397K | $149K-58.0% | $355K+74.0% | $204K | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | $2.9M | $1.5M-80.8% | $7.9M+600.9% | $1.1M-96.2% | $29.6M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $13.2M | $18.6M-10.8% | $20.8M+6.2% | $19.6M+5.9% | $18.5M+23.0% | $15.1M-3.7% | $15.7M-77.1% | $68.3M+39.2% | $49.1M+152.1% | $19.5M+80.8% | $10.8M+60.8% | $6.7M |
| SG&A Expenses | $12.7M | $11.8M-0.5% | $11.9M+0.8% | $11.8M+0.9% | $11.7M+8.5% | $10.8M-36.0% | $16.8M+14.5% | $14.7M+51.4% | $9.7M+54.9% | $6.3M-4.5% | $6.6M+109.4% | $3.1M |
| Operating Income | -$23.0M | -$28.9M-16.3% | -$24.8M+17.9% | -$30.3M-4728.9% | -$627K+96.5% | -$17.9M+40.8% | -$30.3M+63.5% | -$82.9M-42.0% | -$58.4M-131.8% | -$25.2M-45.5% | -$17.3M-76.3% | -$9.8M |
| Net Income | -$26.0M | -$34.4M-5.7% | -$32.5M+1.4% | -$32.9M-8862.5% | $376K+102.1% | -$18.2M+40.8% | -$30.8M+62.8% | -$82.8M-40.4% | -$59.0M-127.9% | -$25.9M-46.7% | -$17.6M-73.1% | -$10.2M |
| EPS (Diluted) | — | -$0.47+11.3% | -$0.53+3.6% | -$0.55 | $0.01+102.6% | -$0.39+51.9% | -$0.81 | N/A | N/A | N/A | N/A | N/A |
Not reported in any period shown, so not listed: Interest Expense, Income Tax.
TTM is the trailing twelve months, Q4 FY2024 through Q3 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CLSD Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $25.1M-26.1% | $34.0M-33.7% | $51.3M+19.6% | $42.9M+122.0% | $19.3M-27.8% | $26.8M-39.3% | $44.1M+9.0% | $40.5M-52.3% | $84.8M+302.8% | $21.1M | N/A |
| Current Assets | $21.3M-29.4% | $30.1M-39.0% | $49.4M+17.2% | $42.1M+132.6% | $18.1M-28.2% | $25.2M-41.3% | $42.9M+9.5% | $39.2M-53.5% | $84.3M+311.7% | $20.5M | N/A |
| Cash & Equivalents | $20.0M-30.8% | $28.9M-40.1% | $48.3M+58.6% | $30.4M+76.1% | $17.3M-23.5% | $22.6M+180.9% | $8.0M-12.8% | $9.2M-73.5% | $34.8M+71.7% | $20.3M+145.3% | $8.3M |
| Accounts Receivable | $507K+8.6% | $467K | $0-100.0% | $10.0M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $64.0M+28.1% | $49.9M+22.7% | $40.7M+725.8% | $4.9M-53.3% | $10.6M-32.4% | $15.6M-23.8% | $20.5M+7.5% | $19.1M+45.0% | $13.2M-77.2% | $57.7M | N/A |
| Current Liabilities | $4.8M-29.6% | $6.8M+17.8% | $5.8M+24.6% | $4.6M-53.3% | $9.9M-8.8% | $10.9M+4.1% | $10.5M-22.5% | $13.5M+150.0% | $5.4M+4.1% | $5.2M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | $3.8M-59.5% | $9.4M+95.9% | $4.8M-36.6% | $7.6M+78.8% | $4.2M | N/A |
| Total Equity | -$38.9M-144.2% | -$15.9M-250.0% | $10.6M-72.1% | $38.0M+333.4% | $8.8M-21.5% | $11.2M-52.8% | $23.6M+10.3% | $21.4M-70.1% | $71.7M+295.5% | -$36.7M-90.8% | -$19.2M |
| Retained Earnings | -$355.3M-10.7% | -$320.9M-11.3% | -$288.4M-12.9% | -$255.5M+0.1% | -$255.9M-7.7% | -$237.7M-14.9% | -$206.9M-66.5% | -$124.2M-90.4% | -$65.2M-65.8% | -$39.4M | N/A |
Not reported in any period shown, so not listed: Inventory, Goodwill.
CLSD Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type.
| Metric | TTM | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$21.3M | -$24.7M-36.2% | -$18.1M-35.7% | -$13.4M-24.5% | -$10.7M+18.2% | -$13.1M+51.5% | -$27.1M+65.8% | -$79.2M-55.0% | -$51.1M-124.9% | -$22.7M-63.4% | -$13.9M-52.4% | -$9.1M |
| Capital Expenditures | $453K | $977K-45.0% | $1.8M+622.4% | $246K | $0-100.0% | $55K+120.0% | $25K-71.6% | $88K-71.2% | $306K+10100.0% | $3K-90.6% | $32K-77.1% | $140K |
| Free Cash Flow | -$21.7M | -$25.7M-28.9% | -$19.9M-46.3% | -$13.6M-26.8% | -$10.7M+18.5% | -$13.2M+51.4% | -$27.1M+65.8% | -$79.3M-54.3% | -$51.4M-126.3% | -$22.7M-63.0% | -$13.9M-50.4% | -$9.3M |
| Investing Cash Flow | $9.3M | -$638K+64.1% | -$1.8M-622.4% | -$246K | $0+100.0% | -$55K-100.2% | $32.9M+975.7% | -$3.8M-118.7% | $20.1M+140.9% | -$49.1M | N/A | N/A |
| Financing Cash Flow | $4.9M | $16.4M+3870.0% | $414K-98.7% | $31.3M+31.8% | $23.8M+202.3% | $7.9M-9.5% | $8.7M-89.4% | $81.8M+1425.2% | $5.4M-93.8% | $86.4M | N/A | N/A |
Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.
TTM is the trailing twelve months, Q4 FY2024 through Q3 FY2025, summed from the four most recent quarterly filings. A row marked — cannot be summed at all, because a quarter in the window reports no per-share figure; a row marked N/A could be summed, but a quarter in the window does not report that metric.
CLSD Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples.
| Metric | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 91.0%-4.6pp | 95.7%+11.0pp | 84.6%-15.4pp | 100.0% | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -1735.7% | -302.0% | -2281.6% | -2.1% | -227.2% | -1394.6% | -276483.3% | -16929.9% | -4845.8% | N/A | N/A |
| Net Margin | -2064.4% | -394.9% | -2482.8% | 1.3% | -230.7% | -1416.0% | -276060.0% | -17094.2% | -4977.3% | N/A | N/A |
| Return on Equity | N/A | N/A | -310.6%-311.6pp | 1.0%+208.8pp | -207.8%+68.0pp | -275.8%+74.8pp | -350.6%-75.2pp | -275.4%-239.3pp | -36.1% | N/A | N/A |
| Return on Assets | -136.7%-41.2pp | -95.5%-31.3pp | -64.2%-65.1pp | 0.9%+95.1pp | -94.2%+20.7pp | -114.9%+72.8pp | -187.7%-42.1pp | -145.6%-115.1pp | -30.5%+53.3pp | -83.8% | N/A |
| Current Ratio | 4.440.0x | 4.42-4.1x | 8.54-0.5x | 9.08+7.3x | 1.82-0.5x | 2.31-1.8x | 4.10+1.2x | 2.90-12.7x | 15.59+11.6x | 3.94 | N/A |
| Debt-to-Equity | N/A | N/A | 3.84+3.7x | 0.13-1.1x | 1.21+0.9x | 0.34-0.1x | 0.40+0.2x | 0.22+0.1x | 0.11 | N/A | N/A |
| FCF Margin | -1543.0% | -242.1% | -1025.7% | -36.3% | -166.9% | -1246.8% | -264293.3% | -14895.4% | -4367.7% | N/A | N/A |
Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.
Note: Shareholder equity is negative (-$38.9M), which causes debt-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.
Similar Companies
Where Clearside Biomed Ranks
Frequently Asked Questions
What is Clearside Biomed's annual revenue?
Clearside Biomed (CLSD) reported $1.7M in total revenue for fiscal year 2024. This represents a -79.8% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is Clearside Biomed's revenue growing?
Clearside Biomed (CLSD) revenue declined by 79.8% year-over-year, from $8.2M to $1.7M in fiscal year 2024.
Is Clearside Biomed profitable?
No, Clearside Biomed (CLSD) reported a net income of -$34.4M in fiscal year 2024.
What is Clearside Biomed's EBITDA?
Clearside Biomed (CLSD) had EBITDA of -$29.2M in fiscal year 2024, measuring earnings before interest, taxes, depreciation, and amortization.
What is Clearside Biomed's gross margin?
Clearside Biomed (CLSD) had a gross margin of 91.0% in fiscal year 2024, indicating the percentage of revenue retained after direct costs of goods sold.
What is Clearside Biomed's free cash flow?
Clearside Biomed (CLSD) recorded an outflow of $25.7M in free cash flow during fiscal year 2024. This represents a -28.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Clearside Biomed's operating cash flow?
Clearside Biomed (CLSD) recorded an outflow of $24.7M in operating cash flow during fiscal year 2024, representing cash used by core business activities.
What are Clearside Biomed's total assets?
Clearside Biomed (CLSD) had $25.1M in total assets as of fiscal year 2024, including both current and long-term assets.
What are Clearside Biomed's capital expenditures?
Clearside Biomed (CLSD) invested $977K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.
How much does Clearside Biomed spend on research and development?
Clearside Biomed (CLSD) invested $18.6M in research and development during fiscal year 2024.
What is Clearside Biomed's current ratio?
Clearside Biomed (CLSD) had a current ratio of 4.44 as of fiscal year 2024, which is generally considered healthy.
What is Clearside Biomed's return on assets (ROA)?
Clearside Biomed (CLSD) had a return on assets of -136.7% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.
Why is Clearside Biomed's debt-to-equity ratio negative or not reported?
Clearside Biomed (CLSD) has negative shareholder equity of -$38.9M as of fiscal year 2024, so no debt-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.
What is Clearside Biomed's Altman Z-Score?
Clearside Biomed (CLSD) has an Altman Z-Score of -22.72, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Clearside Biomed's Piotroski F-Score?
Clearside Biomed (CLSD) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Clearside Biomed's earnings high quality?
Clearside Biomed (CLSD) reported a net loss of $34.4M while operations used $24.7M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Clearside Biomed?
Clearside Biomed (CLSD) scores 44 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.